Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review
Immune checkpoint inhibitors, widely used in the treatment of malignancies, can improve the prognosis of patients, while it also can induce various immune-related adverse events, and type 1 diabetes induced by anti-programmed cell death protein-1 is a rare but severe complication. Here we reported a...
Saved in:
Main Authors: | Zhi-Kai Zheng (Author), Jiong-Liang Wang (Author), Wen-Xuan Li (Author), Tian-Qing Wu (Author), Min-Shan Chen (Author), Zhong-Guo Zhou (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
by: Lulu Xie, et al.
Published: (2022) -
Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation
by: Fei Song, et al.
Published: (2023) -
Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
by: Yang Z, et al.
Published: (2022) -
Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1
by: Jiong Li, et al.
Published: (2024) -
Intrahepatic cholangiocarcinoma after the Fontan procedure
by: Yuichi Shibui, et al.
Published: (2019)